Description

AF12198 is a potent, selective and specific peptide antagonist for human type I interleukin-1 receptor (IL1-R1) (IC50=8 nM) but not the human type II receptor (IC50=6.7 µM) or the murine type I receptor (IC50>200 µM). AF12198 inhibits IL-1-induced IL-8 production (IC50=25 nM) and IL-1-induced intercellular adhesion molecule-1 (ICAM-1) expression (IC50=9 nM) in vitro. AF12198 has anti-inflammatory activities and blocks responses to IL-1 in vivo[1].–80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture and light, under nitrogen)–COVID-19-immunoregulation–C96H123N19O22—-[1]F Aimbire, et al. Low level laser therapy (LLLT) decreases pulmonary microvascular leakage, neutrophil influx and IL-1beta levels in airway and lung from rat subjected to LPS-induced inflammation. Inflammation|[2]A L Akeson, et al.AF12198, a novel low molecular weight antagonist, selectively binds the human type I interleukin (IL)-1 receptor and blocks in vivo responses to IL-1. J Biol Chem. 1996 Nov 29;271(48):30517-23.–185413-30-3–1895.12–99.75–O=C(N1[C@@H](CCC1)C(NCC(N[C@H](C(N[C@H](C(N[C@@H](CCC(N)=O)C(N2[C@@H](CC2)C(N[C@H](C(N[C@@H](C)C(N[C@@H](CC(C)C)C(N3[C@@H](CCC3)C(N[C@H](C(N)=O)CC(C)C)=O)=O)=O)=O)CC4=CC=C(C=C4)O)=O)=O)=O)CC5=CC=C(C=C5)O)=O)CC6=CNC7=CC=CC=C67)=O)=O)[C@H]([C@H](O)C)NC([C@@H](NC([C@H](CCC(O)=O)NC([C@@H](NC(C)=O)CC8=CC=CC=C8)=O)=O)CC9=CNC=CC=CC=C9)=O–Inflammation/Immunology–DMSO : 100 mg/mL (ultrasonic)–Interleukin Related–IL-1;IL-6;IL-8–Immunology/Inflammation–Peptides